TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: three or more consultations with specialist doctor
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: being hospitalised
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Recurrence rate of pterygium
Endpoint domain: Mortality/survival
Primary endpoint: Change in patients' knowledge, attitudes, and behavior concerning health promotion
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Vagal modulation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Temporal dynamics of heart rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Creation of advance directives
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Detection of frontal lobe damage
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Decrease in plasma lipid peroxides
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Labor duration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: ReHo values
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: anxiety sensitivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: negative automatic thoughts
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: perfectionism scores
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: binge remission
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Knowledge-test score change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Preference for WB format
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Time spent on WB modules
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Cook scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: time to spontaneous void
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Postoperative tramadol requirements
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Efficacy of dalfampridine-ER
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adverse events of dalfampridine-ER
Endpoint domain: Adverse events/effects
Primary endpoint: AUC(0,∞) of 5-HMT
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: C(max) of 5-HMT
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Health-related quality of life (HRQL) score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Proportion of children with limitations in 4 attributes or more
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Treatment-emergent all-causality grade ≥ 3 adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Recommended care for falls
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Recommended care for urinary incontinence (UI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: pain perception
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: postoperative side‐to‐side anterior laxity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: gingival overgrowth
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Alcohol screening
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Brief intervention
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: recurrent headaches
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Visceral adipose tissue
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Duration of local numbness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Activities of daily living scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Motor scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: operative costs
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: complete wound closure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: estradiol level decrease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: estrone level decrease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: estrone sulfate level decrease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Systemic exposure (AUC0-t and Cmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Physiologic arousal measured by tonic GSR
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Renal glucose excretion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Prosthesis failures
Endpoint domain: Adverse events/effects
Primary endpoint: Implant losses
Endpoint domain: Adverse events/effects
Primary endpoint: Mean change in Hb levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Average severity of pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in pain (>/=50%)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: apoprotein B
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: lipoprotein (a)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Incidence of breast-feeding
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: perceived pain levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: caregiver distress scores
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Recurrence of AF
Endpoint domain: Mortality/survival
Primary endpoint: IL-6 levels reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Platelet preservation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: IL-2 and C3a levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Sensitivity in predicting lesion dignity of HCC-lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Nonpain symptom and satisfaction scores
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Severe dyspepsia pain intensity increases
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Blood concentrations of tamoxifen and N-desmethyltamoxifen
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Diastolic perfusion time at ischemic threshold
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: VO2peak (Peak Oxygen Consumption)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: subjective craving induced by alcohol priming
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: blood-cortisol levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Diminishment of visual analogue scale scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Less consumption of PCA morphine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Less demand of PCA morphine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Relief of menopausal symptoms
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Increase in bone mineral density (BMD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Support for couples coping with cancer
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Healthy backpack use habits score
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Days without asthma symptoms (DWAS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: children's reported intake of varieties of vegetables
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: children's daily servings of sugar‐sweetened beverages
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: plaque index score reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: gingivitis severity reduction (bleeding sites)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Effectiveness of itraconazole treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: quadriceps peak torque
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Latency of muscle motor-evoked potentials
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Threshold of muscle motor-evoked potentials
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: elevated cholesterol
Endpoint domain: Adverse events/effects
Primary endpoint: elevated triglycerides
Endpoint domain: Adverse events/effects
Primary endpoint: decreased platelets
Endpoint domain: Adverse events/effects
Primary endpoint: local pain at 24h post-administration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: swelling at multiple time points post-administration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: itching at multiple time points post-administration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Self-esteem scores improvement
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Costs of surgery
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Participation in sports
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Discomfort with visual aids during sports
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: BMI percentage decrease
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: percent body fat decrease
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in inflammatory acne lesion counts
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Improvement of the quality of life (Skindex-29 scores)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: coronary endothelial function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: tNAA concentration in CGM
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: myo-inositol concentration in NAWM
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Expanded Disability Status Scale score
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: AFAP values
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total work of breathing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Imposed work of breathing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ART adherence and retention
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Percentage of time at the sedation target
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Post-operative dysphagia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Post-operative heartburn
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: decrease in plasma concentrations of sICAM‐1
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: decrease in plasma concentrations of sVCAM‐1
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: decrease in plasma concentrations of sTM
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Reduction in BPSD scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Related caregiver distress
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Fasting blood glucose (FBG) levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Distance visual acuity improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Near visual acuity improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Physical function deterioration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Non-serious adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Decrease in conduct problems
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of acute GVHD
Endpoint domain: Adverse events/effects
Primary endpoint: Change from partial to complete remission
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Mean infant Hb at 3 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Odds for anemia at 3 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Duration of early morning stiffness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: SMHGT strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PRTEE scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean BCVA change at 48 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean central foveal thickness (CFT) decrease from baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Macular sensitivity improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Postoperative fibrin formation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Increase in S(I)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Increase in RBP4 gene expression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: cumulative 5-year risk of prostate cancer diagnosis
Endpoint domain: Mortality/survival
Primary endpoint: Symptoms of poor glycemic control
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Active synthesis of 92‐kD gelatinase
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Intact survival at school age
Endpoint domain: Mortality/survival
Primary endpoint: gains in cognition
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: gains in real-world functioning
Endpoint domain: Life impact
Endpoint subdomain: Functional outcomes
Primary endpoint: Number of individuals with AD dementia
Endpoint domain: Mortality/survival
Primary endpoint: VAS-rated arousal
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: light reflex amplitude
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean PPI
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean ML
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Inspiratory muscle strength (Pimax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Gene expression changes in immune response and inflammation pathways
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: period of postoperative epidural anesthesia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: levels of serum interleukin‐6
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: levels of C‐reactive protein
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pruritus improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ECBI Intensity scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ECBI Problem scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Twenty-four-hour seizure freedom
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: One-hour seizure remission
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Composite side effects
Endpoint domain: Adverse events/effects
Primary endpoint: post-operative pyuria
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: post-SWL fever
Endpoint domain: Adverse events/effects
Primary endpoint: Clinical response at week 14 (ASAS 20)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma creatine kinase activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Satisfactory response to treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Conversion from positive to negative for Coccidioides species
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Spectral edge frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Verbal sedation score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Severity of myoclonic movements
Endpoint domain: Adverse events/effects
Primary endpoint: Neutrophil elastase concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Interleukin 8 concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: C3d release
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Cumulative 5-year survival
Endpoint domain: Mortality/survival
Primary endpoint: Objective response at 12 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: hot-flush frequency and severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total oxycodone consumption
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: enrollment rates
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: plasma epinephrine level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reproducibility of positive response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reproducibility of negative response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Overall Survival (OS) time
Endpoint domain: Mortality/survival
Primary endpoint: New-onset Atrial Fibrillation (AF)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Improvement of arm and hand function
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Risk of developing shoulder pain
Endpoint domain: Adverse events/effects
Primary endpoint: High-grade dysplasia detection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: ADHD rating scale response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Diastolic filling impairment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Reduction in hospital-acquired infections (HAIs)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Reduction in days of antibiotic treatment
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Prosthodontic maintenance and success
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Gastric cavity and gastric mucosal surface visibility scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Complete tumor eradication
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: apoB concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: tissue factor pathway inhibitor (TFPI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Prevalence of grade-III or IV heterotopic ossification
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total rhinitis and asthma symptom severity scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Overall event-free survival (EFS) at 4 years
Endpoint domain: Mortality/survival